IA
FATE icon

IFP Advisors’s Fate Therapeutics FATE Stock Holding History

IFP Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-800
Closed -$10K – 2680
2018
Q4 		$10K Sell
800
-3,200
-80% -$44.6K ﹤0.01% 2500
2018
Q3 		$65K Sell
4,000
-12,000
-75% -$142K ﹤0.01% 1743
2018
Q2 		$181K Buy
+16,000
New +$176K 0.01% 1114

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IFP Advisors's FATE Position: Q1 2026 in Review

IFP Advisors increased its Fate Therapeutics (FATE) stake by 22% in Q1 2026, buying an estimated $197 and bringing the position to 908 shares worth $1.09K. The position accounts for ﹤0.01% of the portfolio, ranked #4189.

IFP Advisors first reported a position in FATE in Q4 2015 and has held it in 29 quarters since. The position peaked at $342K in Q3 2018. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • IFP Advisors held 908 shares of Fate Therapeutics worth $1.09K as of Q1 2026.
  • IFP Advisors bought 162 Fate Therapeutics shares in Q1 2026, an estimated $197.
  • Fate Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #4189 holding.
  • IFP Advisors first reported a position in Fate Therapeutics in Q4 2015 and has held it in 29 quarters since.
  • IFP Advisors's Fate Therapeutics position peaked at $342K in Q3 2018.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.